Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Publication | Open Access

DOI Full Paper Access

349

Citations

References

2018

Year

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, Philip J. Mease, Atul Deodhar, Walter P. Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé,

The Lancet

InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseSpondyloarthritisMedicineRheumatic DiseasesInterleukin-17a AntagonistInflammatory Rheumatic DiseasePaediatric RheumatologySclerodermaPsoriatic ArthritisAxial SpondyloarthritisOrthopaedic SurgeryRheumatoid ArthritisPhase 3Week Results